Relationship between interleukin-6 and cardiac involvement in systemic sclerosis

Rheumatology (United Kingdom)

Volumn 52, Issue 7, 2013, Pages 1296-1302

  Jurisic, Zrinka ^a   Martinovic Kaliterna, Dusanka ^a   Marasovic Krstulovic, Daniela ^a   Perkovic, Dijana ^a   Tandara, Leida ^a   Salamunic, Ilza ^a   Carevic, Vedran ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Cardiac involvement; Interleukin 6; Systemic sclerosis; Tissue Doppler echocardiography

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 6; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; IL6 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART RIGHT VENTRICLE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; SYSTOLE; TISSUE DOPPLER IMAGING; VELOCITY; BLOOD; DOPPLER ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84891724242     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket131     Document Type: Article

References (20)

1. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology 2006;45:14-7.
2. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011;2011:721608.
3. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
4. Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21:S39-41.
7. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7: 79-108.
8. Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23: 685-713.
9. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33.
10. Alam M, Wardell J, Andersson E et al. Effects of first myocardial infarction on left ventricular systolic and diastolic function with the use of mitral annular velocity determined by pulsed wave Doppler tissue imaging. J Am Soc Echocardiogr 2000;13:343-52.
11. Bulkley BH, Ridolfi RL, Salyer WR. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976;53:484-90.
12. Barnes TC, Spiller DG, Anderson ME et al. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis. Ann Rheum Dis 2011; 70:366-72.
13. Allanore Y, Meune C, Vonk MC et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
14. de Groote P, Gressin V, Hachulla E et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008;67:31-6.
15. Meune C, Avouac J, Wahbi K et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008;58: 1803-9.
16. Rosato E, Maione S, Vitarelli A et al. Regional diastolic function by tissue Doppler echocardiography in systemic sclerosis: correlation with clinical variables. Rheumatol Int 2009;29:913-9.
17. Raymond RJ, Dehmer GJ, Theoharides TC et al. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 2001;141: 435-8.
18. Allanore Y, Meune C. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009;27: 59-63.
19. Valentini G, Vitale DF, Giunta A et al. Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve. Ann Rheum Dis 1996; 55:455-60.
20. Bosello S, De Santis M, Lama G et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six month follow-up open-label trial. Arthritis Res Ther 2010;2: R54.